Release Date: December 23, 2025
Expiration Date: December 23, 2026
Activity Overview
This educational activity is an archive of the live presentation held on Tuesday, December 9, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward medical oncologists, surgical oncologists, advanced practice providers, nurses, and other HCPs involved in the treatment and management of early-stage breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Integrate biomarkers into clinical practice to stratify recurrence risk and tailor multidisciplinary treatment strategies for patients with early-stage HR+/HER2- breast cancer.
- Develop individualized treatment plans for patients with early-stage HR+/HER2- breast cancer based on latest clinical trial evidence and guideline recommendations.
- Implement evidence-based strategies to monitor and manage adverse events associated with treatments for early-stage HR+/HER2- breast cancer to ensure optimal patient outcomes and quality of life.

GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here